KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
22 Feb 2024
Historique:
pubmed: 11 3 2024
medline: 11 3 2024
entrez: 11 3 2024
Statut: epublish

Résumé

Oncogenic

Identifiants

pubmed: 38464238
doi: 10.21203/rs.3.rs-3931415/v1
pmc: PMC10925460
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM132261
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211670
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227184
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009035
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA259111
Pays : United States

Auteurs

Konstantin Budyagan (K)

Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.

Alexa C Cannon (AC)

Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.

Adam Chatoff (A)

Department of Cancer & Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.

Nathaniel W Snyder (NW)

Department of Cancer & Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.

Alison M Kurimchak (AM)

Cancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.

James S Duncan (JS)

Cancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.

Jonathan Chernoff (J)

Cancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.

Classifications MeSH